In this Issue:
This review discusses evidence in support of the
use of eculizumab (Soliris®), an anti-C5 monoclonal
antibody, in the treatment of paroxysmal nocturnal
haemoglobinuria and atypical haemolytic uraemic
syndrome. The pathophysiology, and hence potential
treatment, of both of these diseases is related via the
complement system. Increased understanding of the
role of complement in the pathogenesis of paroxysmal
nocturnal haemoglobinuria and atypical haemolytic
uraemic syndrome facilitated the development of
eculizumab, the first successful targeted therapy
for complement-mediated diseases.
Please login below to download this issue (PDF)